Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise

Enliven Therapeutics Inc. stocks have been trading up by 15.77 percent following highly promising clinical trial progress news.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading ELVN

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Positive updated Phase 1 ENABLE data for ELVN-001 in heavily pretreated CML patients showed strong molecular responses, good tolerability, and FDA alignment on a Phase 3 ENABLE-2 trial expected to start in the second half of the year.
Shares of Enliven Therapeutics jumped about 15% to $42.50 after the Phase 1 ENABLE clinical update, signaling strong trader interest in ELVN.
Stifel initiated coverage on ELVN with a Buy rating and a $60 price target, calling ELVN-001 well positioned as a complementary option to CML drug Scemblix.
Mizuho lifted its ELVN price target to $62 from $45 and kept an Outperform rating, as part of a broader Buy consensus with a mean target near $58.8.
The company priced an upsized offering of about 8.93M shares and 1.73M pre-funded warrants near $37.50, for expected gross proceeds of roughly $400M.

Live Update At 14:03:45 EDT: On Friday, June 12, 2026 Enliven Therapeutics Inc. stock [NASDAQ: ELVN] is trending up by 15.77%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ELVN has traded like a biotech on the verge of a major inflection. In late May, the stock drifted in the low-$40s, then faded into the mid-$30s. That changed fast once new ELVN-001 data hit. On 2026/06/11, Enliven Therapeutics spiked from a prior close near $35–$37 into the low-$40s, then on 2026/06/12 pushed as high as $47.36 before closing at $46.80. That is classic momentum after a real catalyst, not just chat-room hype.

Intraday on 2026/06/12, ELVN showed a strong stair-step pattern. It opened near $40, shook out weak hands below $40, then trended up through the morning and held the mid-$40s all afternoon with repeated higher lows. That tells traders dip buyers were in control.

More Breaking News

Fundamentals show a typical clinical-stage biotech profile. Enliven Therapeutics posted a Q1 2026 net loss of roughly $23.6M, driven by about $20.7M in research and $7.1M in G&A. Operating cash flow was about -$19.3M, but the balance sheet was strong even before the new deal, with $132.2M in cash and roughly $452.4M including short-term investments, minimal liabilities, and no debt. A sky-high current ratio above 40 shows ample liquidity to keep funding ELVN-001 development, especially when combined with the new $400M raise. For traders, that reduces bankruptcy risk and keeps the focus firmly on data and headlines.

Why Traders Are Watching ELVN Now

ELVN is having a textbook biotech breakout driven by real news, not rumors. The main driver is ELVN-001, Enliven Therapeutics’ lead drug candidate for chronic myeloid leukemia. The company reported updated Phase 1 ENABLE data in heavily pretreated patients, showing strong molecular response rates and a clean tolerability profile. That matters because these are tough, previously treated CML cases where many drugs fail.

Even more important for traders, the FDA has now aligned with Enliven on the Phase 3 path. Regulators agreed on an 80 mg once-daily dose, the target patient population, and key design details for the pivotal ENABLE-2 trial, expected to start in the second half of 2026. When the agency and a company are rowing in the same direction, late-stage development risk drops. The market picked up on that fast.

Shares of ELVN jumped about 15% to $42.50 on the Phase 1 news and FDA alignment. Premarket trading also showed sharp gains once that 80 mg Phase 3 dose confirmation hit the tape. From a trading standpoint, that’s a clean example of a binary catalyst repricing the stock.

Wall Street has leaned in as well. Stifel initiated coverage on Enliven Therapeutics with a Buy rating and a $60 target, arguing ELVN-001 fits nicely alongside Novartis’s Scemblix as a complementary option. Mizuho raised its price target to $62 from $45 and reiterated an Outperform rating. Across the Street, ELVN now carries an overall Buy consensus with an average target around $58.7–$58.8, well above recent prices even after the run.

There is also a major capital move in play. Enliven Therapeutics priced an upsized underwritten deal of about 8.93M common shares at $37.50, plus 1.73M pre-funded warrants, for expected gross proceeds around $400M and an extra 1.6M-share underwriters’ option. Yes, that is dilutive. But the timing — immediately after strong ELVN-001 data and a surge in ELVN’s price — shows the company is locking in cash while sentiment is hot, likely to fund Phase 3 and beyond.

Conclusion

For active traders, ELVN is a live case study in how real biotech catalysts drive big moves. Enliven Therapeutics delivered positive Phase 1 ENABLE data, secured FDA alignment on a registrational Phase 3 ENABLE-2 trial for ELVN-001, and then quickly raised about $400M at roughly $37.50 to fund the work. The stock responded with a 15% jump to $42.50 on the news and extended toward the high-$40s in the next session, while intraday action showed sustained buying pressure rather than one-and-done spike behavior.

At the same time, Enliven Therapeutics remains a loss-making, clinical-stage name. Q1 2026 numbers show negative EPS and operating losses, with heavy research spend and no operating revenue. ELVN is being valued on potential — the chance that ELVN-001’s strong molecular responses, safety profile, and possible best-in-class activity against resistant CML mutations like T315I eventually translate into an approved, commercial drug.

That’s exactly the kind of setup momentum traders study: real data, clear near-term catalysts like the upcoming EHA presentation, supportive analysts, and a fully funded runway. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. But as Tim Sykes likes to say, “The market doesn’t care about your hopes, only your risk management.” Any trader watching ELVN needs a plan, defined risk, and the discipline to cut losses fast if the story or the chart breaks. This coverage is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!